Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 13;35(32):3982-3987.
doi: 10.1016/j.vaccine.2017.05.087. Epub 2017 Jun 13.

Impact and cost-effectiveness of rotavirus vaccination in Bangladesh

Clint Pecenka  1 , Umesh Parashar  2 , Jacqueline E Tate  2 , Jahangir A M Khan  3 , Devin Groman  4 , Stephen Chacko  5 , Md Shamsuzzaman  6 , Andrew Clark  7 , Deborah Atherly  4
Affiliations

Impact and cost-effectiveness of rotavirus vaccination in Bangladesh

Clint Pecenka et al. Vaccine. .

Abstract

Introduction: Diarrheal disease is a leading cause of child mortality globally, and rotavirus is responsible for more than a third of those deaths. Despite substantial decreases, the number of rotavirus deaths in children under five was 215,000 per year in 2013. Of these deaths, approximately 41% occurred in Asia and 3% of those in Bangladesh. While Bangladesh has yet to introduce rotavirus vaccination, the country applied for Gavi support and plans to introduce it in 2018. This analysis evaluates the impact and cost-effectiveness of rotavirus vaccination in Bangladesh and provides estimates of the costs of the vaccination program to help inform decision-makers and international partners.

Methods: This analysis used Pan American Health Organization's TRIVAC model (version 2.0) to examine nationwide introduction of two-dose rotavirus vaccination in 2017, compared to no vaccination. Three mortality scenarios (low, high, and midpoint) were assessed. Benefits and costs were examined from the societal perspective over ten successive birth cohorts with a 3% discount rate. Model inputs were locally acquired and complemented by internationally validated estimates.

Results: Over ten years, rotavirus vaccination would prevent 4000 deaths, nearly 500,000 hospitalizations and 3 million outpatient visits in the base scenario. With a Gavi subsidy, cost/disability adjusted life year (DALY) ratios ranged from $58/DALY to $142/DALY averted. Without a Gavi subsidy and a vaccine price of $2.19 per dose, cost/DALY ratios ranged from $615/DALY to $1514/DALY averted.

Conclusion: The discounted cost per DALY averted was less than the GDP per capita for nearly all scenarios considered, indicating that a routine rotavirus vaccination program is highly likely to be cost-effective. Even in a low mortality setting with no Gavi subsidy, rotavirus vaccination would be cost-effective. These estimates exclude the herd immunity benefits of vaccination, so represent a conservative estimate of the cost-effectiveness of rotavirus vaccination in Bangladesh.

Keywords: Bangladesh; Cost-effectiveness; DALY; Rotavirus; Vaccination.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
One-way sensitivity analysis of cost per DALY over 10 Years.
See this image and copyright information in PMC

References

    1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet (London, England) 2015;385:430–40. http://dx.doi.org/10.1016/S0140-6736(14)61698-6. - DOI - PubMed
    1. Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62:S96–S105. - PMC - PubMed
    1. Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Seattle (WA): IHME, University of Washington. Available at: <http://vizhub.healthdata.org/gbd-compare/>; 2016 [accessed 20.01.17].
    1. World Health Organization. Rotavirus deaths by country 2000–2013. Available at: <http://www.who.int/immunization/monitoring_surveillance/rotavirus_deaths...> [accessed 08.02.2017].
    1. International Vaccine Access Center Johns Hopkins Bloomberg School of Public Health. State of rotavirus vaccine use and impact evaluations. Baltimore; 2016.

Publication types

Substances